Rafael Bejar, M.D info ., Ph.D., Kristen Stevenson, M.S., Omar Abdel-Wahab, M.D., Naomi Galili, Ph.D.D., Ph.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D., Azra Raza, M.D., Ross L. Levine, M.D., Donna Neuberg, Sc.D., and Benjamin L. Ebert, M.D., Ph.D.: Clinical Aftereffect of Point Mutations in Myelodysplastic Syndromes Myelodysplastic syndromes are clinically heterogeneous disorders for which treatments are tailored to the predicted prognosis for each patient.
One eligibility necessity is that applications come from countries that have a Gross National Income per capita equal to or less than U.S. $5,000. Because the initial awards in September 2001, 33 grants have been made to experts in Asia, Africa, Eastern European countries and Central and SOUTH USA. More info on the CIPRA system is at ‘In many countries with high prices of HIV/AIDS, the baseline clinical data and research infrastructure needed to accurately characterize the epidemic lack,’ noted NIAID Director Anthony S. Fauci, M.D. CIPRA tackles this issue by providing support, including teaching, tailored to the precise needs of the recipient nation.